Quality of snacking matters more than quantity or frequency, study shows

As­traZeneca’s PD-L1 Imfinzi failed a Phase III tri­al in non-small cell lung can­cer (NSCLC) when in­ves­ti­gat­ed con­cur­rent­ly with chemora­dio­ther­a­py (CRT) as the com­pa­ny worked to

Sanofi’s Modulus plant has been established with funding of €500m. Credit: HJBC/Shutterstock. Sanofi has announced the inauguration of its new modular vaccine and biomedicine production